Mary Anne Heino
Net Worth
Last updated:
What is Mary Anne Heino net worth?
The estimated net worth of Ms. Mary Anne Heino is at least $68,031,222 as of 8 Nov 2024. She owns shares worth $24,530,880 as insider, has earned $32,060,342 from insider trading and has received compensation worth at least $11,440,000 in Lantheus Holdings, Inc..
What is the salary of Mary Anne Heino?
Ms. Mary Anne Heino salary is $1,430,000 per year as Chief Executive Officer, Pres & Director in Lantheus Holdings, Inc..
How old is Mary Anne Heino?
Ms. Mary Anne Heino is 65 years old, born in 1960.
What stocks does Mary Anne Heino currently own?
As insider, Ms. Mary Anne Heino owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | Chief Executive Officer, Pres & Director | 443,436 | $55.32 | $24,530,880 |
What does Lantheus Holdings, Inc. do?
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Mary Anne Heino insider trading
Lantheus Holdings, Inc.
Ms. Mary Anne Heino has made 65 insider trades between 2017-2024, according to the Form 4 filled with the SEC. Most recently she sold 7,487 units of LNTH stock worth $646,278 on 8 Nov 2024.
The largest trade she's ever made was exercising 88,968 units of LNTH stock on 27 Mar 2023. As of 8 Nov 2024 she still owns at least 443,436 units of LNTH stock.
Lantheus Holdings key executives
Lantheus Holdings, Inc. executives and other stock owners filed with the SEC:
- Mr. Robert J. Marshall Jr., CFA (58) Chief Financial Officer & Treasurer
- Ms. Mary Anne Heino (65) Chief Executive Officer, Pres & Director